Cantargia AB

Equities

CANTA

SE0006371126

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:34 2024-05-15 am EDT			5-day change	1st Jan Change
3.54 ^SEK	-1.23%		-1.94%	-5.30%

Apr. 17	Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	CI
Apr. 10	Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	CI

Cantargia AB Announces Executive Changes

October 20, 2020 at 09:39 am EDT

Cantargia AB (publ) announced that the Nomination Committee has been appointed ahead of the 2021 Annual General Meeting, and consists of, Marianne Nilsson (Swedbank Robur Fonder), Jannis Kitsakis (Fjärde AP-fonden), Alexander Mata (Alecta Pensionsförsäkring, Ömsesidigt) and Magnus Persson (Chairman of the Board).

Latest news about Cantargia AB

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	Apr. 17	CI
Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	Apr. 10	CI
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer	Apr. 08	CI
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis	Apr. 02	CI
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia	Mar. 27	CI
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis	Mar. 14	CI
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer	Mar. 05	CI
Transcript : Cantargia AB, 2023 Earnings Call, Feb 22, 2024	Feb. 22
Cantargia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
Cantargia Secures US Approval to Start Patient Recruitment for Pancreatic Cancer Therapy	Feb. 20	MT
Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab	Feb. 20	CI
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy	Feb. 12	CI
Cantargia Reports Phase I Clinical Progress in the CAN10 Project	Jan. 09	CI
Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10	Nov. 24	CI
Cantargia Maintains Patent for Cancer Treatment Amid Withdrawal of Third-party Appeal	Nov. 20	MT
Transcript : Cantargia AB, Q3 2023 Earnings Call, Nov 10, 2023	Nov. 10
Cantargia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
Cantargia Seeks SEK59 Million from Share Sale	23-10-31	MT
Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer	23-09-27	CI
Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR	23-09-20	CI
Cantargia's Investigational Blood Cancer Drug Wins $1.1 Million External US Grant	23-09-18	MT
Cantargia AB Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant	23-09-18	CI
Cantargia Gains Orphan Drug Designation in US for Systemic Sclerosis Treatment	23-09-06	MT
Cantargia ABExpands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases	23-09-05	CI
Transcript : Cantargia AB, H1 2023 Earnings Call, Aug 22, 2023	23-08-22

Chart Cantargia AB

Duration

Period

More charts

Company Profile

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

Sector

Biotechnology & Medical Research

Calendar

2024-05-21 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.54 SEK

Average target price

12.67 SEK

Spread / Average Target

+257.82%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CANTARGIA AB	-5.30%	60.87M
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
BIONTECH SE	-12.64%	22.22B
ARGENX SE	+0.44%	22.27B
GENMAB A/S	-4.18%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-8.58%	17.24B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B
LEGEND BIOTECH CORPORATION	-23.95%	8.34B

Bio Therapeutic Drugs